These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 24961506)

  • 1. Frequent incidence of escape mutants after successful hepatitis B vaccine response and stopping of nucleos(t)ide analogues in liver transplant recipients.
    Ishigami M; Honda T; Ishizu Y; Onishi Y; Kamei H; Hayashi K; Ogura Y; Hirooka Y; Goto H
    Liver Transpl; 2014 Oct; 20(10):1211-20. PubMed ID: 24961506
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Escape hepatitis B virus mutations in recipients of antibody to hepatitis B core antigen-positive liver grafts receiving hepatitis B immunoglobulins.
    Roche B; Roque-Afonso AM; Sebagh M; Delvart V; Duclos-Vallee JC; Castaing D; Samuel D
    Liver Transpl; 2010 Jul; 16(7):885-94. PubMed ID: 20583085
    [TBL] [Abstract][Full Text] [Related]  

  • 3. De novo hepatitis b prophylaxis with hepatitis B virus vaccine and hepatitis B immunoglobulin in pediatric recipients of core antibody-positive livers.
    Lee S; Kim JM; Choi GS; Park JB; Kwon CH; Choe YH; Joh JW; Lee SK
    Liver Transpl; 2016 Feb; 22(2):247-51. PubMed ID: 26600319
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Complete hepatitis B virus prophylaxis withdrawal in hepatitis B surface antigen-positive liver transplant recipients after longterm minimal immunosuppression.
    Lenci I; Baiocchi L; Tariciotti L; Di Paolo D; Milana M; Santopaolo F; Manzia TM; Toti L; Svicher V; Tisone G; Perno CF; Angelico M
    Liver Transpl; 2016 Sep; 22(9):1205-13. PubMed ID: 27272189
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Response to an experimental HBV vaccine permits withdrawal of HBIg prophylaxis in fulminant and selected chronic HBV-infected liver graft recipients.
    Stärkel P; Stoffel M; Lerut J; Horsmans Y
    Liver Transpl; 2005 Oct; 11(10):1228-34. PubMed ID: 16184571
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevention of de novo hepatitis B in recipients of core antibody-positive livers with lamivudine and other nucleos(t)ides: a 12-year experience.
    Chang MS; Olsen SK; Pichardo EM; Stiles JB; Rosenthal-Cogan L; Brubaker WD; Guarrera JV; Emond JC; Brown RS
    Transplantation; 2013 Apr; 95(7):960-5. PubMed ID: 23545507
    [TBL] [Abstract][Full Text] [Related]  

  • 7. De novo activation of HBV with escape mutations from hepatitis B surface antibody after living donor liver transplantation.
    Ueda Y; Marusawa H; Egawa H; Okamoto S; Ogura Y; Oike F; Nishijima N; Takada Y; Uemoto S; Chiba T
    Antivir Ther; 2011; 16(4):479-87. PubMed ID: 21685535
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sustained and focused hepatitis B virus nucleocapsid-specific T-cell immunity in liver transplant recipients compared to individuals with chronic and self-limited hepatitis B virus infection.
    Bihl F; Loggi E; Chisholm JV; Biselli M; Morelli MC; Cursaro C; Terrault NA; Bernardi M; Bertoletti A; Andreone P; Brander C
    Liver Transpl; 2008 Apr; 14(4):478-85. PubMed ID: 18324666
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatitis B virus quasispecies evolution after liver transplantation in patients under long-term lamivudine prophylaxis with or without hepatitis B immune globulin.
    Buti M; Tabernero D; Mas A; Homs M; Prieto M; Rodríguez-Frías F; Casafont F; Casillas R; González A; Miras M; Herrero JI; Castells L; Esteban R
    Transpl Infect Dis; 2015 Apr; 17(2):208-20. PubMed ID: 25641570
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High incidence of treatment-induced and vaccine-escape hepatitis B virus mutants among human immunodeficiency virus/hepatitis B-infected patients.
    Lacombe K; Boyd A; Lavocat F; Pichoud C; Gozlan J; Miailhes P; Lascoux-Combe C; Vernet G; Girard PM; Zoulim F
    Hepatology; 2013 Sep; 58(3):912-22. PubMed ID: 23468093
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Nucleos(t)ides as prophylaxis for the reactivation of hepatitis B virus in immunosuppressed patients].
    Fan LY; Zhou Z; Zhong S; Ling N; Wang ZY; Shi XF; Zhang DZ; Ren H
    Zhonghua Gan Zang Bing Za Zhi; 2009 Jun; 17(6):429-33. PubMed ID: 19567021
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatitis B vaccination.
    Romanò L; Paladini S; Galli C; Raimondo G; Pollicino T; Zanetti AR
    Hum Vaccin Immunother; 2015; 11(1):53-7. PubMed ID: 25483515
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Different effect of HBV vaccine after liver transplantation between chronic HBV carriers and non-HBV patients who received HBcAb-positive grafts.
    Ishigami M; Kamei H; Nakamura T; Katano Y; Ando H; Kiuchi T; Goto H
    J Gastroenterol; 2011 Mar; 46(3):367-77. PubMed ID: 20835733
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination of lamivudine and adefovir without hepatitis B immune globulin is safe and effective prophylaxis against hepatitis B virus recurrence in hepatitis B surface antigen-positive liver transplant candidates.
    Gane EJ; Patterson S; Strasser SI; McCaughan GW; Angus PW
    Liver Transpl; 2013 Mar; 19(3):268-74. PubMed ID: 23447403
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An efficacy and cost-effectiveness analysis of combination hepatitis B immune globulin and lamivudine to prevent recurrent hepatitis B after orthotopic liver transplantation compared with hepatitis B immune globulin monotherapy.
    Han SH; Ofman J; Holt C; King K; Kunder G; Chen P; Dawson S; Goldstein L; Yersiz H; Farmer DG; Ghobrial RM; Busuttil RW; Martin P
    Liver Transpl; 2000 Nov; 6(6):741-8. PubMed ID: 11084061
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HBIg discontinuation with maintenance oral anti-viral therapy and HBV vaccination in liver transplant recipients.
    Weber NK; Forman LM; Trotter JF
    Dig Dis Sci; 2010 Feb; 55(2):505-9. PubMed ID: 19802696
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatitis B virus S mutants in liver transplant recipients who were reinfected despite hepatitis B immune globulin prophylaxis.
    Ghany MG; Ayola B; Villamil FG; Gish RG; Rojter S; Vierling JM; Lok AS
    Hepatology; 1998 Jan; 27(1):213-22. PubMed ID: 9425940
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination prophylaxis with Hepatitis B immunoglobulin and lamivudine after liver transplantation minimizes HBV recurrence rates unless evolution of pretransplant lamivudine resistance.
    Seehofer D; Rayes N; Steinmüller T; Müller AR; Jonas S; Settmacher U; Neuhaus R; Berg T; Neuhaus P
    Z Gastroenterol; 2002 Sep; 40(9):795-9. PubMed ID: 12215948
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevention of hepatitis B virus infection from hepatitis B core antibody-positive donor graft using hepatitis B immune globulin and lamivudine in living donor liver transplantation.
    Suehiro T; Shimada M; Kishikawa K; Shimura T; Soejima Y; Yoshizumi T; Hashimoto K; Mochida Y; Maehara Y; Kuwano H
    Liver Int; 2005 Dec; 25(6):1169-74. PubMed ID: 16343068
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiviral treatment for hepatitis B virus recurrence following liver transplantation.
    Lee S; Kwon CH; Moon HH; Kim TS; Roh Y; Song S; Shin M; Kim JM; Park JB; Kim SJ; Joh JW; Lee SK
    Clin Transplant; 2013; 27(5):E597-604. PubMed ID: 24093615
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.